ArticleJournal of family medicine and primary care2025
Subacute thyroiditis after COVID-19 - Clinical, laboratory and ultrasound aspects.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Subacute thyroiditis (SAT) is a self-limited inflammatory thyroid disease that follows or co-exists with a viral infection. COVID-19 has numerous multisystemic effects, including thyroid disorders. Possible mechanisms involved in COVID-19 infection-associated thyroid dysfunction include: apoptosis, inflammatory reaction and damage to follicular cells, direct effect of the virus, or interaction with thyroid angiotensin converting enzyme 2 (ACE2) receptors, respectively. Methodology and Results: In the period November 2021-February 2022, 12 patients with SAT associated with COVID-19 were evaluated in our department (11 women, one man); mean age 50 ± 13.1 years. The mean time between COVID-19 infection and the onset of subacute thyroiditis was 23 ± 10.2 days. The most common symptoms presented by affected patients were: fever, pain in the thyroid, and complaints associated with thyrotoxicosis. All patients presented severe inflammatory syndrome, but the clinical and biochemical picture of thyrotoxicosis was more severe compared to other viral subacute thyroiditis. In 60% of cases, 2D ultrasonography was suggestive for subacute thyroiditis, but the parameters of Share-Wave Elastography (SWE) confirmed the diagnosis in 100% of cases (mean thyroid stiffness 234.2 ± 34.5 kPa). Under steroid therapy, during follow-up, thyroid stiffness gradually decreased at 4 weeks (130.38 ± 15.4 kPa), respectively, at 8 weeks (64.7 ± 5.3 kPa). The clinical outcome was favorable in all cases. Two patients developed hypothyroidism and were treated accordingly. SAT is characterized by a significantly increased stiffness of the thyroid. Discussion: The results of this study documented a significant difference in thyroid tissue stiffness between. SAT at baseline and values recorded at the follow-up visit. It should be noted that changes in the elastic properties of the thyroid parenchyma were associated with gradual normalization of biochemical parameters. The early diagnosis of SAT associated with COVID-19 is crucial, as prompt treatment with glucocorticoids leads to complete resolution of the disease. Conclusion: SWE sonoelastography is useful in the positive diagnosis of subacute thyroiditis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.